Skip to main content
MarketStoryBook

128940.KS in “GLP-1 Eats Everything”

Hanmi Pharm. Co., Ltd.

Bull sideFadingExposure: not rated yet

Hanmi has a differentiated obesity pipeline led by long-acting multi-agonist candidates targeting GLP-1, GIP and glucagon pathways.

128940.KS impact map — “GLP-1 Eats Everything”

How this story travels from the headline to 128940.KS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading 128940.KS impact map…

Price history, marked with story events

Aug 25, 2025 – Aug 25, 2026 · 243 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

GLP-1 Eats Everything

Appetite suppression as a macro variable.

BULL side — Hanmi has a differentiated obesity pipeline led by long-acting multi-agonist candidates targeting GLP-1, GIP and glucagon pathways.

Read the full GLP-1 Eats Everything story